---
title: "Hikma Advances $250m Buyback, Tightening Share Count"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285939986.md"
description: "Hikma Pharmaceuticals has executed a $250 million share buyback, repurchasing 388,189 shares between May 5-8, 2026, at prices ranging from 1,402.5 to 1,445 pence per share. This buyback aims to reduce the share count, enhancing earnings per share and capital returns for investors. Since February, Hikma has bought back 5,735,311 shares for £73.7 million. Following the latest buyback, the company will have 216,151,142 shares in issue. Analysts rate HIK stock as a Buy with a £1870.00 price target, though some concerns about cash generation and technical trends persist."
datetime: "2026-05-11T12:12:29.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285939986.md)
  - [en](https://longbridge.com/en/news/285939986.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285939986.md)
---

# Hikma Advances $250m Buyback, Tightening Share Count

### Claim 55% Off TipRanks

-   Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
-   Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

Hikma Pharmaceuticals ( (GB:HIK) ) has shared an update.

Hikma Pharmaceuticals has continued executing its $250 million share repurchase programme, buying back 388,189 ordinary shares between 5 and 8 May 2026 on the London Stock Exchange and CBOE Europe at prices around 1,402.5 to 1,445 pence per share. The company plans to cancel these shares, which will reduce the number of shares in issue and is likely to enhance earnings per share and capital returns for investors.

Since launching the buyback in late February, Hikma has acquired 5,735,311 shares for a total cost of £73.7 million, while also retaining 12,833,233 shares in treasury. Following settlement and cancellation of the latest tranche, Hikma will have 216,151,142 ordinary shares in issue, a lower share count that tightens the free float and underscores management’s confidence in the company’s valuation and cash generation.

The most recent analyst rating on (GB:HIK) stock is a Buy with a £1870.00 price target. To see the full list of analyst forecasts on Hikma Pharmaceuticals stock, see the GB:HIK Stock Forecast page.

**Spark’s Take on HIK Stock**

According to Spark, TipRanks’ AI Analyst, HIK is a Neutral.

The score is held back primarily by weakening cash generation and a notably bearish technical trend (oversold and trading below key moving averages). These are partially offset by attractive valuation (low P/E and strong dividend yield) and a constructive earnings-call outlook supported by guidance comfort and a GBP 250m buyback, despite near-term injectable headwinds.

To see Spark’s full report on HIK stock, click here.

**More about Hikma Pharmaceuticals**

Hikma Pharmaceuticals is a multinational generic and specialty pharmaceuticals manufacturer listed in London and on Nasdaq Dubai. The company focuses on supplying injectable medicines, branded and non-branded generics, and other critical treatments to markets in the Middle East, North Africa, Europe and the U.S., with an emphasis on hospital and specialty care segments.

**Average Trading Volume:** 1,371,829

**Technical Sentiment Signal:** Hold

**Current Market Cap:** £3.04B

Learn more about HIK stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [HIK.UK](https://longbridge.com/en/quote/HIK.UK.md)

## Related News & Research

- [REG - Hikma Pharmaceutical - Holding(s) in Company](https://longbridge.com/en/news/289564831.md)
- [US Supreme Court backs generic drugmaker in 'skinny label' patent case](https://longbridge.com/en/news/288735377.md)
- [Supermarkets take £800m hit from fat jabs](https://longbridge.com/en/news/289338334.md)
- [REG - Wellington Mngmnt Gp DCC PLC - Form 8.3 - DCC plc](https://longbridge.com/en/news/289313369.md)
- [09:30 ETLung Cancer Research Foundation Announces Request for Proposals Open for ALK-Positive Lung Cancer Research Grant](https://longbridge.com/en/news/289198209.md)